Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

nium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional ... ingredients (API) released unaudited preliminary financial results for ... Fiscal Year 2015 Ended September 30, 2014 ... compared with $14.7 million in 1Q14 with gross ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Lower Body InjuriesCINCINNATI, May 5 In comparison to ... have lower body injuries, such as in their ankles ... which was conducted to determine if different body parts ... so that prevention strategies can be developed, was presented ...
... Disease Presented at Pediatric Academic Societies, Annual MeetingBALTIMORE, ... a recent study it sponsored, performed by the ... assessing risk factors for respiratory syncytial virus (RSV) ... 33 weeks gestational age [GA] or later. The ...
Cached Medicine Technology:The Injured Obese Child: Let's Give Him Some Ankle Support 2The Injured Obese Child: Let's Give Him Some Ankle Support 3MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants 2MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants 3
(Date:12/25/2014)... 25, 2014 Residents at ... recently showed their generous spirit by providing holiday ... County Parenting Network- Grandparents Raising Grandchildren program. , ... around the largest Christmas tree on the campus ... by residents of the Abernethy Village Association (AVA). ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... 24, 2014 New studies reveal that women ... loss related depression (March 6, 2014, JAMA Otolaryngology*). And although ... loss (about 50 percent according to recent polls) facing hearing ... how a person feels and relates to the world. People ... are also made by way of:, , ...
(Date:12/24/2014)... UWDress.com, the famous women’s dress supplier, has presented its new ... wedding gown promotion. , For those who prefer ... way, the collection should be a great choice. The dresses ... they are available with custom service. , Now, all the ... to 75% off; most of them come in hot designs. ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
Dengue, the mosquito-transmitted lethal disease that has claimed 15 lives and afflicted 1,000 people in West Bengal so far, has been declared an epidemic by the state government.// ,State Health Dir...
... discovered a new way to test the stem cells ... ,The researchers had used a non-invasive imaging ... after being injected into the body to treat animal ... ,In the study, researchers surgically induced acute ...
... alcohol-based hand sanitizer gel significantly reduces the spread of ... 292 families studied, half of the families, which used ... % reduction in the spread of illness related to ... sanitizer were excluded from the study. Half the families ...
... aortic valve in the heart is the valve that governs the ... which supplies blood to various organs of the body. // It ... rest of the body. ,The effective functioning of the heart ... valve can be defective in some cases, leading to a compromise ...
... India's Health Minister Anbumani Ramadoss Monday said that ... its national immunisation programme// as it has been ... ,Addressing the valedictory function of an Indian Council ... training workshop on laboratory diagnosis of leptospirosis at ...
... of the clinical study carried out by Professor Ian Reed ... Zealand has found that the drug Zometa manufactured by Novartis ... by Procter and Gamble. ,Paget's disease is a ... than the normal and the new bone replacement does not ...
Cached Medicine News:Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Percutaneous aortic valve replacement- a revolution in Cardiac Surgery 2
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
... The Black Max is a ... for the rapid dissection of ... The Black Max not only ... also allows for the control ...
Legend Gold is the most powerful of the new motors. It runs at an impressive 76,000 rpm at 120 psi/8 bar. It is also smaller than the Midas Rex Classic motor, with an enhanced ergonomic design....
... Gold Touch motor is the first true high-speed, ... Gold Touch is comparable to Legend Gold and ... The telescoping lever design provides ergonomic positioning and ... Midas Rex Classic, the Legend Gold Touch is ...
Medicine Products: